PDS Biotechnology Approves Equity Plan Amendment at Meeting

PDS Biotechnology ( (PDSB) ) has provided an update.

On June 11, 2025, PDS Biotechnology Corporation held its annual stockholders meeting, where several key proposals were approved. Notably, the stockholders approved an amendment to the company’s 2014 Equity Incentive Plan, increasing the number of shares issuable under the plan by 3,144,049, bringing the total to 9,709,584 shares. This move is expected to enhance the company’s ability to attract and retain talent. Additionally, the election of two Class A directors, the ratification of KPMG US LLP as the independent auditor, and the approval of executive compensation were also confirmed, reflecting strong shareholder support for the company’s strategic direction.

The most recent analyst rating on (PDSB) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on PDS Biotechnology stock, see the PDSB Stock Forecast page.

Spark’s Take on PDSB Stock

According to Spark, TipRanks’ AI Analyst, PDSB is a Neutral.

PDSB’s overall score reflects the typical high-risk, high-reward nature of early-stage biotech firms. The company’s strong clinical progress and cash position are significant positives, but financial sustainability and valuation concerns due to ongoing losses and reliance on external funding temper the outlook. Technical indicators suggest some positive momentum, albeit with caution.

To see Spark’s full report on PDSB stock, click here.

More about PDS Biotechnology

PDS Biotechnology Corporation operates in the biotechnology industry, focusing on developing innovative immunotherapies for cancer and infectious diseases. The company is known for its proprietary Versamune® platform, which is designed to activate the immune system to recognize and attack diseased cells.

Average Trading Volume: 465,551

Technical Sentiment Signal: Sell

Current Market Cap: $76.79M

See more insights into PDSB stock on TipRanks’ Stock Analysis page.